These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31989330)

  • 1. Biorelevant In Vitro Release Testing and In Vivo Study of Extended-Release Niacin Hydrophilic Matrix Tablets.
    Milanowski B; Hejduk A; Bawiec MA; Jakubowska E; Urbańska A; Wiśniewska A; Garbacz G; Lulek J
    AAPS PharmSciTech; 2020 Jan; 21(3):83. PubMed ID: 31989330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation development and human in vitro-in vivo correlation for a novel, monolithic controlled-release matrix system of high load and highly water-soluble drug niacin.
    Turner S; Federici C; Hite M; Fassihi R
    Drug Dev Ind Pharm; 2004 Sep; 30(8):797-807. PubMed ID: 15521326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An In Vitro Dissolution Method for Testing Extended-Release Tablets Under Mechanical Compression and Sample Friction.
    Gao Z; Cao LNY; Liu X; Tian L; Rodriguez JD
    J Pharm Sci; 2022 Jun; 111(6):1652-1658. PubMed ID: 34742730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Drug Properties and Formulation on In Vitro Drug Release and Biowaiver Regulation of Oral Extended Release Dosage Forms.
    Lin Z; Zhou D; Hoag S; Qiu Y
    AAPS J; 2016 Mar; 18(2):333-45. PubMed ID: 26769249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of in vitro-in vivo correlation for extended-release niacin after administration of hypromellose-based matrix formulations to healthy volunteers.
    Kesisoglou F; Rossenu S; Farrell C; Van Den Heuvel M; Prohn M; Fitzpatrick S; De Kam PJ; Vargo R
    J Pharm Sci; 2014 Nov; 103(11):3713-3723. PubMed ID: 25256703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Release characteristics of quetiapine fumarate extended release tablets under biorelevant stress test conditions.
    Garbacz G; Kandzi A; Koziolek M; Mazgalski J; Weitschies W
    AAPS PharmSciTech; 2014 Feb; 15(1):230-6. PubMed ID: 24297600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet.
    Menon R; Tolbert D; Cefali E
    Biopharm Drug Dispos; 2007 Sep; 28(6):297-306. PubMed ID: 17571283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended-Release Case Study.
    Kim S; Sharma VD; Lingineni K; Farhan N; Fang L; Zhao L; Brown JD; Cristofoletti R; Vozmediano V; Ait-Oudhia S; Lesko LJ; Trame MN; Schmidt S
    J Clin Pharmacol; 2019 Sep; 59(9):1266-1274. PubMed ID: 31087554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Robustness of barrier membrane coated metoprolol tartrate matrix tablets: Drug release evaluation under physiologically relevant in vitro conditions.
    Klein S; Seeger N; Mehta R; Missaghi S; Grybos R; Rajabi-Siahboomi A
    Int J Pharm; 2018 May; 543(1-2):368-375. PubMed ID: 29630933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An understanding of modified release matrix tablets behavior during drug dissolution as the key for prediction of pharmaceutical product performance - case study of multimodal characterization of quetiapine fumarate tablets.
    Kulinowski P; Woyna-Orlewicz K; Rappen GM; Haznar-Garbacz D; Węglarz WP; Dorożyński PP
    Int J Pharm; 2015 Apr; 484(1-2):235-45. PubMed ID: 25701626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of the Oral Pharmacokinetics and Food Effects of Gabapentin Enacarbil Extended-Release Tablets Using Biorelevant Dissolution Tests.
    Yamaguchi Ikeuchi S; Kambayashi A; Kojima H; Oku N; Asai T
    Biol Pharm Bull; 2018; 41(11):1708-1715. PubMed ID: 30381671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissolution profiles of nonprescription extended-release niacin and inositol niacinate products.
    Poon IO; Chow DS; Liang D
    Am J Health Syst Pharm; 2006 Nov; 63(21):2128-34. PubMed ID: 17057051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of hydrogel-based controlled-release niacin tablets.
    Khullar P; Khar RK; Agarwal SP
    Drug Dev Ind Pharm; 1998 May; 24(5):479-83. PubMed ID: 9876611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses.
    Garbacz G; Wedemeyer RS; Nagel S; Giessmann T; Mönnikes H; Wilson CG; Siegmund W; Weitschies W
    Eur J Pharm Biopharm; 2008 Oct; 70(2):421-8. PubMed ID: 18582568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of in vitro biorelevant dissolution and in silico PBPK model of carvedilol to predict bioequivalence of oral drug products.
    Ibarra M; Valiante C; Sopeña P; Schiavo A; Lorier M; Vázquez M; Fagiolino P
    Eur J Pharm Sci; 2018 Jun; 118():176-182. PubMed ID: 29605455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of the biopharmaceutics characteristics of solid oral Modified-Release drug products in approved US FDA NDAs designated as Extended-Release or Delayed-Release formulations.
    Ahmed N; Ly H; Pan A; Chiang B; Raines K; Janwatin T; Hamed S; Dave K
    Eur J Pharm Biopharm; 2023 Dec; 193():294-305. PubMed ID: 37984592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
    Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mathematical Model-Based Accelerated Development of Extended-release Metformin Hydrochloride Tablet Formulation.
    Chen W; Desai D; Good D; Crison J; Timmins P; Paruchuri S; Wang J; Ha K
    AAPS PharmSciTech; 2016 Aug; 17(4):1007-13. PubMed ID: 26729531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.